Karagkiozaki / Logothetidis Horizons in Clinical Nanomedicine

Erscheinungsjahr 2014
ISBN: 978-981-4411-57-8
Verlag: Pan Stanford Publishing
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 372 Seiten

Nanomedicine—the application of nanotechnology to health sciences—has the potential to address many important medical problems by exploiting the advanced physicochemical characteristics of nanostructured materials and devices. It can revolutionize conventional medicine by offering cutting-edge developments in the processes of diagnosing, treating, and preventing diseases, injuries, or genetic disorders. Thus, clinical nanomedicine holds promise to preserve and improve human health.

This book provides a comprehensive overview on the forefront developments of nanotechnology in various domains of clinical medicine, such as cardiology, oncology, pharmacology, immunology, dermatology, virology, hematology, orthopedics, embryology and congenital defects, dentistry, and tissue engineering. It also extensively discusses the toxicology aspects of engineered nanomaterials.

Autoren/Hrsg.

Karagkiozaki, Varvara

Logothetidis, Stergios

Fachgebiete

• Technische Wissenschaften Technik Allgemein Nanotechnologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Medizintechnik, Biomedizintechnik, Medizinische Werkstoffe
• Technische Wissenschaften Sonstige Technologien | Angewandte Technik Medizintechnik, Biomedizintechnik
• Technische Wissenschaften Maschinenbau | Werkstoffkunde Technische Mechanik | Werkstoffkunde Materialwissenschaft: Biomaterialien, Nanomaterialien, Kohlenstoff
• Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Biotechnologie Biotechnologie: Mikrotechnologie, Nanobiotechnologie

Inhaltsverzeichnis

Introduction to Nanomedicine. Nanomedicine Targets Atherosclerosis. Nanomedicine Advancements in Cancer Diagnosis and Treatment. Nanomedicine and Blood Diseases. Nanomedicine and Orthopaedics. Nanoscaffolds and Other Nano-Architectures for Tissue Engineering Related Applications. Oncolytic Viruses as Nanomachines for Cancer Treatment. Nanopharmaceutics Issues in Dermatology. Nanomedicine and Embryology. Nanomedicine and HIV/ AIDS. Biocompatible 2D and 3D Scaffolds for Medical Devices. Regenerative Dentistry. Toxicity and Genotoxicity of Metal and Metal Oxide Nanomaterials. Analogies in the Adverse Immune Effects of Wear Particles, Environmental Particles and Medicinal Nanoparticles.

Über Autor(innen)

Varvara Karagkiozaki is the head of the Nanomedicine Group at the Laboratory for Thin Films—Nanosystems and Nanometrology (LTFN), Aristotle University of Thessaloniki (AUTh), Greece. She is a specialist cardiologist with a BSc in medicine, an MSc in nanotechnologies, and a PhD in nanomedicine with distinction from AUTh. Dr. Karagkiozaki has given numerous invited talks in international nanomedical conferences and published several academic research papers in peer-reviewed journals. She has delivered lectures at Nanomedicine Summer Schools and at the Nanosciences and Nanotechnologies postgraduate program of AUTh. She was chair of the Organizing Committee of Nanomedicine and Bioelectronics Workshops for many editions of the International Conference on Nanosciences and Nanotechnologies.

Stergios Logothetidis is the founder and director of the LTFN Laboratory, at AUTh, Greece. His research activity is complemented by more than 680 papers and review articles in international journals and conferences. He has given more than 150 invited talks. He is a referee for 30 scientific journals. Prof. Logothetidis has been the coordinator in more than 60 R&D projects funded by the European Commission in the fields of nanotechnologies, organic electronics, and nanomedicine. He is the founder and director of the "Nanosciences and Nanotechnologies" postgraduate program of AUTh and founder and coordinator of the International Research Network on Nanotechnologies "NANONET" with 350 members from universities, research institutes, and companies.